Channels
All News
In Focus
Special
AI
Bioregnum
Biotech Voices
Cell/Gene Tx
China
Coronavirus
Deals
Diagnostics
Discovery
FDA+
Financing
Health Tech
Law
Letters to the Editor
Manufacturing
Marketing
Nikkei Biotechnology
Opinion
Outsourcing
Peer Review
People
Pharma
R&D
Startups
Weekly
Webinars
Biopharma Jobs
More
Work at Endpoints
Letter to Editors
Editorial Standards
IPO Tracker
Webinars
Events
Sponsored Posts
Advertise
Privacy Policy
Endpoints Merch
About Us
Help
SIGN UP
LOG IN
Takeda claims PhIII success in dengue vaccine months after Dengvaxia implosion for rival Sanofi
7 years ago
R&D
As Pfizer kills failed PhIII programs for Bavencio, where do they go from here in R&D?
7 years ago
Bioregnum
R&D
Pfizer and Lilly's tanezumab largely makes the efficacy cut in second PhIII study, but safety issues continue to ...
7 years ago
R&D
Voyager bags a 'transformational' $1.8B gene therapy pact with Neurocrine
7 years ago
Pharma
Cell/Gene Tx
Gottlieb lays out real world evidence priorities for 2019 with an eye on digital tools
7 years ago
Pharma
Gates and Chinese private equity group cheer on Lyndra's PhII plans with $55M raise
7 years ago
Financing
Celgene rolls along with another epigenetic preclinical deal featuring a Canadian biotech
7 years ago
Discovery
Trevena forges plan to take once-rejected opioid across finish line, after 'productive' FDA meeting
7 years ago
Pharma
The next 5 years: Higher R&D productivity is here to stay, emerging biotechs and new tech will have a big impact. But ...
7 years ago
Startups
R&D
Unfazed by Brexit blues, UK biotech trade group celebrates boisterous year of venture dollars with record £1.1B ...
7 years ago
Financing
The FDA is back in business; Allogene given the green signal to test lymphoma drug in humans
7 years ago
News Briefing
EMA says symbolic goodbye to London HQ as it sets up shop in Amsterdam
7 years ago
Pharma
Disgraced at Vertex, Ian Smith’s career implosion ends with swift exile from biotech boards
7 years ago
People
Imbruvica regimen wins FDA approval as first non-chemotherapy treatment for untreated patients with common form of ...
7 years ago
Pharma
Zai Lab nabs speedy China regulatory review for PARP drug Zejula
7 years ago
China
Pharma
After securing quick OK for PNH patients, Alexion's Ultomiris succeeds in aHUS pivotal study
7 years ago
R&D
By the numbers for 2018: The top 100 venture players in biotech — and who's been paying the piper in cancer R&D?
7 years ago
Financing
Scoop: GSK’s venture team at SR One in talks to spin off from its big pharma founder, now under new R&D management
7 years ago
Financing
Pharma
Novartis sounds alarm on unsustainable drug supply chain if no-deal Brexit becomes reality
7 years ago
Pharma
A stem cell therapy preps debut in Japanese market to the dismay of US researchers
7 years ago
Cell/Gene Tx
AbbVie shares slide on sliding Humira revenue; Deerfield is making a big investment in new device startups
7 years ago
News Briefing
GSK, Sanofi enlist in a big genomics project aiming to map genes of half a million Finns
7 years ago
Discovery
Vertex COO Ian Smith ousted due to 'personal behavior'; CFO Mats Blom exits Zealand Pharma; Katrine Bosley abruptly ...
7 years ago
Peer Review
The antibiotics R&D effort is broken. Here's one market solution that might fix it
7 years ago
Bioregnum
Opinion
First page
Previous page
979
980
981
982
983
984
985
Next page
Last page